ライフサイエンスコーパス: lymph node dissection

1 will determine the true benefit of extended lymph node dissection.

2 lanoma who subsequently underwent completion lymph node dissection.

3 ated biochemical cure rates after systematic lymph node dissection.

4 ity and better quality of life than axillary lymph node dissection.

5 ts initially managed without retroperitoneal lymph node dissection.

6 xamined receipt of radiotherapy and axillary lymph node dissection.

7 e what should be considered the standard for lymph node dissection.

8 those treated with radical hysterectomy and lymph node dissection.

9 may require chemotherapy, radiotherapy, and lymph node dissection.

10 l nodes (SNs) were considered for completion lymph node dissection.

11 nt metastasis and with documentation of full lymph node dissection.

12 n enjoy significant long-term survival after lymph node dissection.

13 isplatin) plus radical cystectomy and pelvic lymph node dissection.

14 that reported in previous series of elective lymph node dissection.

15 All patients were offered axillary lymph node dissection.

16 he initial group went on to undergo axillary lymph node dissection.

17 axillary nodal involvement remains complete lymph node dissection.

18 cessary complications of a complete axillary lymph node dissection.

19 d have been spared the morbidity of axillary lymph node dissection.

20 1987 and underwent radical prostatectomy and lymph node dissection.

21 nt poverty underwent mastectomy and axillary lymph node dissection.

22 y invasive), and sentinel versus full pelvic lymph node dissection.

23 rative-intent lung resection with systematic lymph node dissection.

24 ases at the time of RARP and extended pelvic lymph node dissection.

25 split-dose GC before surgical resection and lymph node dissection.

26 adical cystectomy or nephroureterectomy with lymph node dissection.

27 ectomy was accompanied by an extended pelvic lymph node dissection.

28 all survival for those treated with axillary lymph node dissection.

29 size continue to mandate completion axillary lymph node dissection.

30 urate, less invasive alternative to axillary lymph node dissection.

31 al excision, sentinel lymph node biopsy, and lymph node dissection.

32 ll patients had breast surgery with axillary lymph node dissection.

33 entinel lymph node biopsy (SLNB) or axillary lymph node dissection.

34 lgrastim followed by radical cystectomy with lymph node dissection.

35 nt radical prostatectomy and extended pelvic lymph node dissection.

36 e, adjuvant chemotherapy, or retroperitoneal lymph-node dissection.

37 omised trials of adjuvant radiotherapy after lymph-node dissection.

38 y a ureteral injury incurred during sentinel-lymph-node dissection.

39 imaging decreases the number of unnecessary lymph node dissections.

40 years) with breast cancer before 52 axillary lymph node dissections.

41 imately 10% of women do not have an axillary lymph node dissection, 11% to 26% do not have their horm

42 Of the 9 patients who underwent lymph node dissection, 4 (44%) had residual nodal diseas

43 or-positive SNs, 11 (78%) underwent complete lymph node dissection; 4 had tumor-positive non-SNs.

44 risk, 0.83 [CI, 0.77 to 0.90]) and axillary lymph node dissection (adjusted relative risk, 0.81 [CI,

45 east cancer, the role of completion axillary lymph node dissection (ALND) after identification of nod

46 ode biopsy (SLNB) alone, SLNB+RLNR, axillary lymph node dissection (ALND) alone, and ALND+RLNR.

47 Axillary lymph node dissection (ALND) as part of surgical treatme

48 SLNB has replaced axillary lymph node dissection (ALND) as the staging modality of

49 (BCRL) is a common complication of axillary lymph node dissection (ALND) but can also develop after

50 entinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND) for invasive breast cancer

51 nformation with less morbidity than axillary lymph node dissection (ALND) for patients with clinicall

52 psy (SLNB) was developed to replace axillary lymph node dissection (ALND) for staging early breast ca

53 Axillary lymph node dissection (ALND) has been a part of breast c

54 Axillary lymph node dissection (ALND) has been a standard procedu

55 Higher lymphedema rates after axillary lymph node dissection (ALND) have been found in Black an

56 des (SLNs) were negative, SLNB with axillary lymph node dissection (ALND) if SLNB or PET was positive

57 ological outcomes after omission of axillary lymph node dissection (ALND) in patients with breast can

58 al nodal irradiation (RNI) and omit axillary lymph node dissection (ALND) in patients with clinically

59 st cancer patients, the role of the axillary lymph node dissection (ALND) in the management of clinic

60 Recent enthusiasm for limiting axillary lymph node dissection (ALND) in women with breast cancer

61 ode dissection (SLND) alone without axillary lymph node dissection (ALND) is noninferior to that of w

62 ACOSOG Z0011 established that axillary lymph node dissection (ALND) is unnecessary in patients

63 ntinel lymph node biopsy (SLNB) and axillary lymph node dissection (ALND) may be because of unrecogni

64 adiotherapy (PMRT), the addition of axillary lymph node dissection (ALND) may result in significant o

65 or macrometastasis (Ma), leading to axillary lymph node dissection (ALND) only when strictly necessar

66 sted of either total mastectomy and axillary lymph node dissection (ALND) or segmental mastectomy and

67 h nodes (SLNs) randomized either to axillary lymph node dissection (ALND) or sentinel lymph node diss

68 sy (SLNB) alone are unknown because axillary lymph node dissection (ALND) was performed in all patien

69 all cases with a tumor-involved SN, axillary lymph node dissection (ALND) was recommended.

70 After NAC, SLN surgery and axillary lymph node dissection (ALND) were planned.

71 LE is a serious complication of axillary lymph node dissection (ALND) with an incidence rate of 2

72 roposed to replace the conventional axillary lymph node dissection (ALND) with its concomitant morbid

73 ed that 20 to 30 cases of SLND with axillary lymph node dissection (ALND) would enable surgeons to id

74 rial in which SNB was compared with axillary lymph node dissection (ALND), four limited meta-analyses

75 sentinel lymph node biopsy (SLNB), axillary lymph node dissection (ALND), or none.

76 with or without SLNB, TLNB, and/or axillary lymph node dissection (ALND).

77 sitive SLN who underwent completion axillary lymph node dissection (ALND).

78 (SLNs) who did and did not undergo axillary lymph node dissection (ALND).

79 ma (BCRL) in patients who underwent axillary lymph node dissection (ALND).

80 (SLN) metastases should not receive axillary lymph node dissection (ALND).

81 (SLN) metastases should not receive axillary lymph node dissection (ALND).

82 ized in 4 groups: SLN-negative with axillary lymph node dissection (ALND; n = 326), SLN-negative with

83 The goals of axillary-lymph-node dissection (ALND) are to maximise survival, p

84 still offer outcomes equivalent to axillary-lymph-node dissection (ALND).

85 sentinel lymph node biopsy [SNB] or axillary lymph node dissection [ALND]) were compared with US and

86 survival for patients treated with sentinel lymph node dissection alone was noninferior to overall s

87 Retroperitoneal lymph node dissection also appears to be worthwhile in c

88 istant disease ('desperation retroperitoneal lymph node dissection'), although the relapse rate is hi

89 s were randomly assigned to receive axillary lymph node dissection and 2404 to receive axillary radio

90 , 744 had been randomly assigned to axillary lymph node dissection and 681 to axillary radiotherapy;

91 N had additional lymph nodes in the complete lymph node dissection and 7.5% of the patients with posi

92 he roles of laparoscopic nephroureterectomy, lymph node dissection and adjuvant chemotherapy in advan

93 Radical cystectomy with an appropriate lymph node dissection and an appropriate form of urinary

94 g AFP and hCG shortly before retroperitoneal lymph node dissection and at the start of each chemother

95 Axillary lymph node dissection and axillary radiotherapy after a

96 idity traditionally associated with regional lymph node dissection and increasing survival in subgrou

97 In conclusion, animals subjected to complete lymph node dissection and irradiation developed changes

98 lly curative resections consisting of portal lymph node dissection and liver parenchymal resections.

99 Lymph node dissection and postimplantation prostatic bio

100 st-conserving surgery combined with axillary lymph node dissection and radiotherapy or mastectomy are

101 Currently, the optimal boundaries of pelvic lymph node dissection and the minimum number of nodes to

102 urvival between those patients who underwent lymph node dissection and those who did not.

103 alized lymph node before completion axillary lymph node dissection and used radiography of the specim

104 e pattern could lead to unnecessary axillary lymph node dissections and lymphedema.

105 went an initial SLNB, 37.2% initial axillary lymph node dissection, and 6.3% no axillary surgery.

106 with residual disease underwent mastectomy, lymph node dissection, and radiotherapy.

107 t chemotherapy reduces the need for axillary lymph node dissection, and SLNB is an accurate method of

108 imary tumor therapy, to not receive axillary lymph node dissection, and to not receive radiation ther

109 thickness, body site, ulceration, performed lymph node dissection, and treatment.

110 opsy, but also lymph-node sampling, axillary-lymph-node dissection, and observation alone.

111 e a separate incision is needed for axillary lymph-node dissection, and postoperative radiotherapy is

112 For selected patients, axillary lymph node dissection appears to have little influence o

113 The therapeutic benefits of lymph node dissection are still controversial.

114 ic or diagnostic guidelines regarding pelvic lymph node dissection are, however, currently available.

115 ignificantly less likely to receive axillary lymph node dissection as determined by logistic regressi

116 arly breast cancer and has replaced complete lymph node dissection as the staging modality of choice

117 Process of care (ie, time to treatment, lymph node dissection), as well as outcome measures (ie,

118 of agreement of what constitutes an adequate lymph node dissection at the time of radical cystectomy

119 Pelvic lymph node dissection at the time of radical cystectomy

120 ll patients who underwent selective sentinel lymph node dissection at the UCSF Melanoma Center from 1

121 ive surgical margin rates, thorough extended lymph node dissection based on tenets of oncological pri

122 e I testis cancer has led to retroperitoneal lymph node dissection being performed mostly after chemo

123 underwent en bloc esophagectomy with radical lymph node dissection between 1988 and 1998.

124 ostatectomy and anatomically extended pelvic lymph node dissection between 1988 and 2010 at two terti

125 rature to clarify the current role of pelvic lymph node dissection both as a staging modality as well

126 We have previously found that axillary lymph node dissection, both clinically and in a mouse mo

127 (SLNs) generally undergo completion axillary lymph node dissection (cALND), either concurrently with

128 Esophagectomy with three-field lymph node dissection can be performed with a low mortal

129 initial reports suggest that an appropriate lymph node dissection can be performed.

130 Axillary lymph node dissection can identify the presence of metas

131 -lymph-node involvement, completion axillary-lymph-node dissection can be omitted or replaced by axil

132 Minimally invasive retroperitoneal lymph node dissection carries safety and oncologic equiv

133 onducted regarding SLN biopsy and completion lymph node dissection (CLND) after a positive sentinel n

134 primarily for patients undergoing completion lymph node dissection (CLND) for node-positive disease a

135 terferon alfa-2b therapy (HDI) or completion lymph node dissection (CLND) for patients with melanoma

136 ic is whether routine 'prophylactic' central lymph node dissection (CLND) in patients without evidenc

137 Completion lymph node dissection (CLND) is recommended for all pati

138 entinel lymph node biopsy (SLNB) or complete lymph node dissection (CLND) to all patients with MCC; h

139 ch patients may most benefit from completion lymph node dissection (CLND).

140 front SLNB and reduces the need for axillary lymph node dissection compared with SLNB prior to NAC.

141 ssively less extensive, with formal axillary lymph node dissection confined to a dwindling group of p

142 Axillary lymph node dissection continues to be routinely applied

143 Retroperitoneal lymph node dissection continues to play a crucial role i

144 he body of literature suggesting an extended lymph node dissection cures more patients than lesser an

145 : What is the effect of different extents of lymph node dissection (D1, D2, and D3 lymphadenectomy) i

146 The optimum extent of lymph-node dissection (D1 vs D2) is controversial.

147 mphadenectomy (the most conservative type of lymph node dissection), D2 lymphadenectomy (but not D3)

148 for intraoperative or postoperative axillary lymph node dissection decisions.

149 Although elective lymph node dissection decreased the rate of recurrence,

150 rker molecular assay to immediate completion lymph-node dissection (dissection group) or nodal observ

151 %) subsequently underwent prostatectomy with lymph node dissection (efficacy analysis cohort).

152 am to determine whether elective (immediate) lymph node dissection (ELND) for intermediate-thickness

153 d radical prostatectomy with extended pelvic lymph node dissection (ePLND) for prostate cancer is sti

154 entinel node biopsy (SNB) to extended pelvic lymph node dissection (ePLND) remains controversial.

155 This was followed by extended pelvic lymph node dissection (ePLND).

156 er (T1 CRC) undergo a radical operation with lymph node dissection, even though only ~ 10% have lymph

157 5% embryonal carcinoma, and retroperitoneal lymph node dissection for clinical stage I disease in Ja

158 eillance rather than primary retroperitoneal lymph node dissection for clinical stage I testis cancer

159 al thyroidectomy with 'therapeutic' cervical lymph node dissection for involved lymph nodes is the st

160 After lateral lymph node dissection for metastatic thyroid cancer, dys

161 sed use of radical prostatectomy with pelvic lymph node dissection for primary management of high-ris

162 nd, SLN biopsy facilitates early therapeutic lymph node dissection for those patients with nodal meta

163 ore likely to recommend prophylactic central lymph node dissection for thyroid cancer regardless of t

164 year suggest that - in high-volume centers - lymph node dissection for urologic cancers is equivalent

165 The value of completion lymph-node dissection for patients with sentinel-node me

166 viously undisputed gold standard of axillary-lymph-node dissection for staging has now been replaced

167 rred in four of 744 patients in the axillary lymph node dissection group and seven of 681 in the axil

168 In the axillary lymph node dissection group, 220 (33%) of 672 patients w

169 ode biopsy group and 7 (37%) in the axillary lymph node dissection group.

170 compared with an expected 2% in the axillary lymph node dissection group.

171 st and regional nodes after BCS and axillary lymph node dissection (Group 1) were compared to nine no

172 natomic surgical resection, (2) had adequate lymph node dissection (>=1 N1 nodal station plus >=3 N2

173 (33%) of 672 patients who underwent axillary lymph node dissection had additional positive nodes.

174 or = 1.5 mm in thickness undergoing elective lymph node dissection had histologically positive nodes

175 The role of pelvic lymph node dissection has evolved over the past 60 years

176 are accepted, an optimal template for pelvic lymph node dissection has not been established.

177 s (SLNs) are recommended to undergo axillary lymph node dissection if extranodal extension (ENE) is p

178 biopsy (followed by an immediate completion lymph node dissection if positive) provided T3 melanoma

179 ers while avoiding the morbidity of axillary lymph node dissection if the nodes do not contain cancer

180 cted to proceed with upfront RC and extended lymph node dissection in conjunction with construction o

181 m radiation, and the role of retroperitoneal lymph node dissection in disseminated nonseminomatous ca

182 evant studies on the role of retroperitoneal lymph node dissection in early and advanced stages of di

183 To reduce extensive lymph node dissection in patients and to decrease subseq

184 it is time to reassess the role of axillary lymph node dissection in patients who undergo conservati

185 Pelvic lymph node dissection in patients with clinically locali

186 ications for omission of completion axillary lymph node dissection in patients with two or fewer node

187 The role of retroperitoneal lymph node dissection in postorchiectomy early-stage non

188 ed surgery and discusses its implications in lymph node dissection in primary and recurrent prostate

189 dings do not support routine use of axillary lymph node dissection in this patient population based o

190 st 20 years, and the controversy of elective lymph node dissections in this disease continues to be d

191 resent role and routine practice of axillary-lymph-node dissection in early breast cancer, the method

192 ive stage I, II, and IV disease who received lymph node dissection increased.

193 Immediate completion lymph-node dissection increased the rate of regional dis

194 Of the 59 patients, 48 had axillary lymph node dissection irrespective of the results of pat

195 Although esophagectomy with three-field lymph node dissection is commonly practiced in Japan, it

196 Complete axillary lymph node dissection is indicated in patients who prese

197 who have a positive sentinel node, axillary lymph node dissection is the present standard.

198 s, a bilateral nerve-sparing retroperitoneal lymph node dissection is the treatment of choice for pat

199 cystectomy remain undefined, and appropriate lymph node dissections laparoscopically have not been un

200 Lymph node dissection (LDN) at the time of a primary mal

201 patients did not undergo subsequent axillary lymph node dissection, leaving 95 patients for further a

202 There is good evidence that a pelvic lymph node dissection limited to the external iliac vein

203 The impact of a locoregional lymph node dissection (LND) has never been defined in th

204 To present recent advances in the field of lymph node dissection (LND) in the context of bladder ca

205 rimary lesions > 1.5 mm thick) scheduled for lymph node dissection (LND) were preoperatively studied

206 ding: What is a 'standard' versus 'extended' lymph node dissection (LND)?

207 Lateral lymph node dissection may be warranted for an upper thyr

208 This suggests that axillary lymph node dissection may not be necessary in patients w

209 Sentinel lymph node dissection may supplant standard axillary dis

210 Minimally invasive inguinal lymph node dissection (MILND) is a novel approach to ing

211 matic sampling [SS], or complete mediastinal lymph node dissection [MLND]) on DFS and OS was also stu

212 oncologic equivalence of SN biopsy and neck lymph node dissection (ND; standard treatment) has never

213 owing radical cystectomy require an extended lymph node dissection, negative surgical margins, and a

214 Black patients were less likely to undergo lymph node dissection (odds ratio [OR], 0.76 [95% CI, 0.

215 A total of 1,019 patients with complete lymph node dissection of American Joint Committee on Can

216 Lymph node dissection of the first basin may differ depe

217 location schedule to receive either axillary lymph node dissection or axillary radiotherapy in case o

218 ratio to SABR or lobectomy with mediastinal lymph node dissection or sampling.

219 cancer (NSCLC) is lobectomy with mediastinal lymph node dissection or sampling.

220 , high body mass index ( P = .039), axillary lymph node dissection ( P = .008), and more severe acute

221 osis ( P = .0404), having undergone axillary lymph node dissection ( P = .0464), and receipt of adjuv

222 body mass index >/= 25 (P = .0236), axillary lymph node dissection (P < .001), regional lymph node ir

223 Axillary lymph node dissection (P < 0.0001), higher body mass ind

224 undergoing postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) for NSGCT to determine

225 y tumor and postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) specimen and assess imp

226 s recommend postchemotherapy retroperitoneal lymph node dissection (PC-RPLND), whereas others omit su

227 40% of all postchemotherapy retroperitoneal lymph node dissections (PC-RPLND).

228 The lymph node dissection performed at the time of radical c

229 node dissection received it, and 86% of the lymph node dissections performed were necessary.

230 ction was not performed, and only 31% of the lymph node dissections performed were necessary.

231 ndings with radical prostatectomy and pelvic lymph node dissection (PLND) histopathology findings.

232 Radical cystectomy with pelvic lymph node dissection (PLND) is the preferred treatment

233 Open radical cystectomy (ORC) and pelvic lymph node dissection (PLND) is the standard treatment f

234 rrence rate and similar survival to axillary lymph node dissection.Preoperative axillary ultrasound a

235 Although axillary lymph node dissection provides excellent regional contro

236 and included wide surgical excision, radical lymph node dissection, radiation therapy, and chemothera

237 urgical approach, particularly the extent of lymph-node dissection, radioactive iodine dosing, and th

238 Facility-level axillary lymph node dissection rates ranged from 7% to 47%, lumpe

239 imaging scenario, all patients who required lymph node dissection received it, and 86% of the lymph

240 Retroperitoneal lymph node dissection remains a prominent treatment moda

241 Radical cystectomy with bilateral pelvic lymph node dissection remains the gold standard for trea

242 Until these become widely available, pelvic lymph node dissection remains the modality of choice for

243 men who have a nerve-sparing retroperitoneal lymph node dissection (RPLND) because more patients on s

244 e relapse rate after primary retroperitoneal lymph node dissection (RPLND) for patients with patholog

245 atients managed primarily by retroperitoneal lymph node dissection (RPLND) or chemotherapy was examin

246 been advocated after primary retroperitoneal lymph node dissection (RPLND) to reduce the risk of rela

247 CG more than 100 ng/mL, redo retroperitoneal lymph node dissection (RPLND), and second-line chemother

248 tate decision making between retroperitoneal lymph node dissection (RPLND), primary chemotherapy, and

249 ght selective use of primary retroperitoneal lymph node dissection (RPLND).

250 diotherapy, chemotherapy, or retroperitoneal lymph node dissection (RPLND).

251 Modified template retroperitoneal lymph node dissections (RPLND) have become increasing ap

252 five had undergone previous retroperitoneal lymph node dissections (RPLNDs).

253 5 or fewer lymph node metastases, systematic lymph node dissection seems worthwhile for persistent MT

254 sy (SLNB) alone or SLNB followed by axillary lymph node dissection (SLNB/ALND) between June 1, 1999,

255 B) alone and after SLNB followed by axillary lymph node dissection (SLNB/ALND).

256 Sentinel lymph node dissection (SLND) accurately identifies nodal

257 with breast-conserving therapy and sentinel lymph node dissection (SLND) alone without axillary lymp

258 ary lymph node dissection (ALND) or sentinel lymph node dissection (SLND) alone.

259 ific antigen (PSA) persistence after salvage lymph node dissection (SLND) and pre-procedure and post-

260 ohort with PSA persistence following salvage lymph node dissection (SLND) and pre/post procedure pros

261 ry dissection (TAD), which includes sentinel lymph node dissection (SLND) and selective localization

262 Sentinel lymph node dissection (SLND) has eliminated the need for

263 Marked variations in sentinel lymph node dissection (SLND) technique have been identif

264 Clinicopathological characteristics of lymph node dissection specimens of 83 patients enrolled

265 centers, but a larger proportion of robotic lymph node dissections surpass the oncologic threshold o

266 obtain prognostic information (ie, axillary lymph node dissection), tends to minimize treatment opti

267 oted significantly more often after axillary lymph node dissection than after axillary radiotherapy a

268 ective series, randomised trials of elective lymph-node dissection, the role of 'sentinel' lymph-node

269 val times with this technique allow sentinel lymph node dissection to be performed on the same day as

270 y followed by completion level I/II axillary lymph node dissection to determine the false-negative ra

271 entinel lymph node, which will help to limit lymph node dissections to those patients with nodal meta

272 d a survival advantage for elective regional lymph node dissection, two randomized trials have not sh

273 Twenty HNSCC patients scheduled for lymph node dissection underwent DCE-MRI, dynamic PET, an

274 of the tumor and suprapancreatic bile duct, lymph node dissection, vascular reconstruction, and subt

275 was 0.43% (95% CI 0.00-0.92) after axillary lymph node dissection versus 1.19% (0.31-2.08) after axi

276 Extent of lymph node dissection was available for patients diagnos

277 n the MR imaging scenario, the necessity for lymph node dissection was based on MR imaging results an

278 ion of the fluorescent lymph nodes, a pelvic lymph node dissection was completed with robotic assista

279 e most common site of first recurrence after lymph node dissection was distant (44% of all patients).

280 In the actual scenario, one necessary lymph node dissection was not performed, and only 31% of

281 In the actual scenario, lymph node dissection was performed at the surgeon's dis

282 A complementary axillary lymph node dissection was performed in all patients to a

283 A RARP including extended pelvic lymph node dissection was performed, with intraoperative

284 negative SLN, unless an immediate completion lymph node dissection was performed.

285 Elective lymph node dissection was the only parameter independent

286 Immediate completion lymph-node dissection was not associated with increased

287 Recurrence and survival after lymph node dissection were analyzed.

288 ion of the primary tumor and extended pelvic lymph node dissection were enrolled.

289 eated by radical prostatectomy and bilateral lymph node dissection were included in this study.

290 undergoing total mastectomy and/or axillary lymph node dissection were randomized to standard drain

291 positive patients and of completion axillary lymph node dissection) were analyzed to rule out differe

292 rmed absence of lymph node metastases (after lymph node dissection) were included, to assess the risk

293 some advocate prophylactic central cervical lymph node dissection, whereas others only rarely recomm

294 ergoes right upper lobectomy and mediastinal lymph node dissection, which demonstrate no clinical or

295 y followed by radical cystectomy with pelvic lymph node dissection, which disclosed residual high-gra

296 ed by breast-conserving surgery and axillary lymph node dissection, which revealed residual disease i

297 Establishing standards for pelvic lymph node dissection will not only increase the consist

298 A standard external iliac and obturator lymph node dissection, with or without extension to hypo

299 detectable SDM and can proceed to completion lymph node dissection without immediate CT or MRI stagin

300 ity to achieve the results of total axillary lymph node dissection without the risks of surgery or ev